Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Bone age necessary to correctly interpret growth status in pediatric Crohn's disease

Measuring bone age should be a standard practice of care for pediatric patients with Crohn's disease, in order to properly interpret growth status and improve treatment, according to a new study from the UCSF Benioff Children's Hospital.

25 May 2012

Measuring bone age should be part of routine care for pediatric patients with Crohn's disease

25 May 2012

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according to a study published online by the journal AIDS, official journal of the International AIDS Society.

23 May 2012

New research reveals effective treatments for gastrointestinal conditions

New research being presented at Digestive Disease Week- (DDW) reveals effective treatments for a number of gastrointestinal conditions, which are often chronic and costly.

22 May 2012

Some patients appear to be more predisposed for recurrent infection from C. diff

University of Cincinnati (UC) researchers have found that some patients appear to be more predisposed for recurrent infection from the bacterium Clostridium difficile, or C. diff, and that it may advance to a more serious inflammatory condition in those individuals.

22 May 2012

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI (golimumab) induced clinical response in a majority of patients with moderately to severely active ulcerative colitis (UC) who had previously failed or were intolerant to conventional agents.

22 May 2012

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS (budesonide) 6 mg tablets will be featured in four poster presentations at the Digestive Disease Week (DDW) Meeting being held at the San Diego Convention Center on May 19 - 22, 2012.

19 May 2012

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference.

19 May 2012

Imedex, Mechanisms in Medicine and Cornerstones launch new YouTube ‘You and IBD’

Cornerstones Health Inc., a nonprofit organization working to improve communication between patients with inflammatory bowel disease (IBD) and physicians who treat IBD, in collaboration with Imedex, LLC and Mechanisms in Medicine Inc., announced the launch of the new YouTube "You and IBD" - Animated IBD Patient Channel.

18 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

Takeda Pharmaceutical Company Limited today announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial evaluated vedolizumab in 1,115 patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

11 May 2012

GOS prompts body's natural killer cells to ward off colon cancer

Researchers at Michigan State University have shown a prebiotic may help the body's own natural killer cells fight bacterial infection and reduce inflammation, greatly decreasing the risk of colon cancer.

4 May 2012

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

InDex Pharmaceuticals today announced that it has been granted a patent by the United States Patent and Trademark Office. The patent provides additional protection for the use of Kappaproct® and additional DNA-based immunomodulatory sequences (DIMS) for the treatment of steroid-resistant inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis, psoriasis, asthma, emphysema and chronic obstructive pulmonary disease.

26 Apr 2012

Early intervention of biologic therapies improves outcome for Crohn's disease

A large-scale study of medical claims data shows that introducing sophisticated biologic therapies early in the course of treatment for Crohn's disease improves response to medication and reduces the need for surgery.

18 Apr 2012

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Winston Pharmaceuticals, Inc.,, announced that the National Institutes of Health has awarded Winston a grant under the Small Business Innovation Research program supporting the development of Civamide, a proprietary TRPV-1 receptor modulator, for the treatment of postherpetic neuralgia of the trigeminal nerve.

9 Apr 2012

Feinstein scientists to present three GBM abstracts at AACR annual meeting

Scientists from the Feinstein Institute for Medical Research will present three abstracts about Glioblastoma multiforme (GBM), the most common and deadly adult brain cancer, at the American Association for Cancer Research (AACR) Annual Meeting to be held from Saturday through Wednesday (March 31- April 4) in Chicago, IL.

5 Apr 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

Basidiobolomycosis appears to be emerging in the Southwestern U.S.

An emerging fungal infection of the gastrointestinal tract that mimics cancer and inflammatory bowel disease appears to be emerging in the Southwestern United States and other desert regions, according to Mayo Clinic researchers in Arizona investigating the disease. The invasive fungus, Basidiobolus ranarum, is typically found in the soil, decaying organic matter and the gastrointestinal tracts of fish, reptiles, amphibians, and bats.

30 Mar 2012

Patients with IBD, other GI disorders may be exposed to higher levels of diagnostic radiation

Patients with inflammatory bowel disease (IBD) and other gastrointestinal (GI) disorders may be exposed to significant doses of diagnostic radiation, according to a new study in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association.

30 Mar 2012

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Allena Pharmaceuticals, Inc., and Althea Technologies today announced a licensing agreement under which Allena has obtained the exclusive worldwide rights to Althea's broad hyperoxaluria portfolio including product patents, regulatory information and development data related to oxalate degrading enzymes.

29 Mar 2012

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Bone age necessary to correctly interpret growth status in pediatric Crohn's disease

Measuring bone age should be part of routine care for pediatric patients with Crohn's disease

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

New research reveals effective treatments for gastrointestinal conditions

Some patients appear to be more predisposed for recurrent infection from C. diff

Data from Janssen’s SIMPONI Phase 3 study on ulcerative colitis

Santarus to present UCERIS Phase III trial data on ulcerative colitis at DDW meeting

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Imedex, Mechanisms in Medicine and Cornerstones launch new YouTube ‘You and IBD’

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Top-line results from Takeda vedolizumab phase 3 trial on Crohn's disease

GOS prompts body's natural killer cells to ward off colon cancer

InDex Pharmaceuticals granted U.S. patent for novel treatment of steroid-resistant inflammation

Early intervention of biologic therapies improves outcome for Crohn's disease

NIH awards Winston SBIR grant to develop Civamide for postherpetic neuralgia of TN

Feinstein scientists to present three GBM abstracts at AACR annual meeting

ChemoCentryx fourth quarter revenues increase to $26.1 million

Basidiobolomycosis appears to be emerging in the Southwestern U.S.

Patients with IBD, other GI disorders may be exposed to higher levels of diagnostic radiation

Althea provides Allena exclusive worldwide rights to broad hyperoxaluria portfolio

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in